XML 74 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaboration Agreements - Accounting for the AstraZeneca Agreements - Additional Information 3 (Detail) - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Manufacturing commercial supplies of products, revenue recognized $ 212,958,000 $ 130,996,000 $ 183,189,000
AstraZeneca Agreements [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Royalty rate against projected net revenues 40.00%    
Co-development services, currently estimated continuation year 2024    
AstraZeneca Agreements [Member] | Manufacturing Commercial Supplies of Products [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Manufacturing commercial supplies of products, revenue recognized $ 0    
AstraZeneca Agreements [Member] | Measurement Input Discount Rate [Member] | Discounted Cash Flow [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Discount rate applied 17.5    
AstraZeneca Agreements [Member] | U.S./RoW and China [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Non-contingent upfront payments received $ 402,200,000    
Variable consideration related to payments for milestones considered probable of being achieved 42,000,000    
Variable consideration related to co-development billings $ 621,600,000